Blog
RSS FeedPosted by Michael Wonder on 09 Jul 2020
Drugmakers appeal limited insurance benefit for dementia drug choline alfoscerate
9 July 2020 - Sixty-six manufacturers of choline alfoscerate, a dementia drug, filed an appeal to the Health Insurance Review ...
Posted by Michael Wonder on 09 Jul 2020
'Xolair’s reimbursement will change treatment paradigm for asthma patients'
9 July 2020 - Novartis Korea will be able to strengthen its position in the severe allergic asthma market with ...
Posted by Michael Wonder on 30 Jun 2020
EMA and Korean Ministry of Food and Drug Safety to share confidential COVID-19 information
30 June 2020 - EMA and the Ministry of Food and Drug Safety of the Republic of Korea have signed ...
Posted by Michael Wonder on 29 Jun 2020
‘Government should lower prices of generic drugs’
29 June 2020 - “Our policy should aim at reaching the OECD average of general drug use, additionally cut generic ...
Posted by Michael Wonder on 14 Jun 2020
Dementia drug choline alfoscerate to get limited insurance benefit
12 June 2020 - The government has allowed choline alfoscerate, a dementia drug, to continue to receive the national health ...
Posted by Michael Wonder on 12 Jun 2020
Orphan drug reimbursements create tough situation for South Korean public budget
12 June 2020 - A data analysis of real-world data found that the rise of orphan drugs in the Republic of ...
Posted by Michael Wonder on 11 Jun 2020
'Imfinzi changed treatment paradigm for non-resectable non-small cell lung cancer'
10 June 2020 - The treatment has also become the first immunotherapy launched in Korea to receive health insurance benefits as ...
Posted by Michael Wonder on 03 Jun 2020
South Korea approves emergency use of Gilead's anti-viral drug to treat COVID-19
3 June 2020 - South Korea said on Wednesday it has approved the emergency use of Gilead Sciences’ remdesivir to ...
Posted by Michael Wonder on 02 Jun 2020
CDK 4/6 inhibitor market to heat up on insurance benefits
2 June 2020 - Despite such high unmet medical needs, the drug has long been out of reach for patients ...
Posted by Michael Wonder on 18 May 2020
Government to re-evaluate dementia drug choline alfoscerate
18 May 2020 - The Ministry of Health and Welfare said it would reassess whether choline alfoscerate, a dementia treatment, ...
Posted by Michael Wonder on 16 May 2020
Cancer patients demand Ono, BMS, MSD share immunotherapy cost
15 May 2020 - Immunotherapies Optivo, marketed by Ono Pharma Korea and BMS Korea, and Keytruda by MSD Korea, have ...
Posted by Michael Wonder on 15 Apr 2020
Review of cancer drug benefits delayed amid social distancing
8 April 2020 - The government has postponed the health authorities’ meeting for a review of anticancer drugs’ benefits initially ...
Posted by Michael Wonder on 26 Mar 2020
Price negotiations begin for breast cancer combo drugs
25 March 2020 - Drug makers and the government will start talks this week to negotiate prices of breast cancer ...
Posted by Michael Wonder on 06 Mar 2020
Gastric cancer drug Liporaxel nears getting insurance benefit
6 March 2020 - Daehwa Pharmaceutical’s Liporaxel (paclitaxel), a treatment for advanced, metastatic and local recurrent gastric cancer, has neared ...
Posted by Michael Wonder on 21 Feb 2020
Regulator OKs Pfizer's Vizimpro as first-line treatment of mutated lung cancer
20 February 2020 - Pfizer Korea said Thursday that the Ministry of Food and Drug Safety has approved Vizimpro (dacomitinib) ...